2019 AGENDA
Philadelphia, 15 - 17 April 2019
Schedule
Create your personal agenda –check the favourite icon
Apr 1513:00
Conference pass
Incorporating AI into early safety screening: OneThree Biotech’s approach to predict organ specific adverse events
Pre-Conference Seminar
Neel Madhukar, CEO, OneThree Biotech
Coryandar Gilvary, Vice President of Computational Biology, OneThree Biotech
Apr 1513:00
Conference pass
Welcome
Insife Workshops
Opening Remarks and Introductions.
Apr 1513:10
Conference pass
Navigating the regulatory compliance minefield
Insife Workshops
Indentification and matienance of ever-changing global regulatory requirements
Apr 1513:30
Conference pass
Starting safety from scratch: how to implement safety programs in startups and grow your PV operations (from one safety professional to an entire team)
Pre-Conference Seminar
Oyinkansola Odebo, Senior Manager Drug Safety, Supernus Pharmaceutical
Apr 1514:00
Conference pass
Data from electronic health records:how to use EHR data, text mining, and patient profiles to improve your safety processes
Pre-Conference Seminar
Rama Vempati, Associate Director, Pharmacyclics
Apr 1514:20
Conference pass
The decentralization of global requirements
Insife Workshops
Understanding changes to ICH policy, tracking local requirements, implementing local QPPV roles, and building good practices for working together in a networked pharma amidst ongoing mergers, acquisitions and licensing agreements
Apr 1515:00
Conference pass
PV Technologies and the Quadruple Bottom Line: Profit, People, Planet, Purpose
Pre-Conference Seminar
Anthony Robinson, Chief Operating Officer, Intrommune Therapeutics
Apr 1515:10
Conference pass
Technology to the rescue
Insife Workshops
Using technology to become inspection ready and increasingly more efficient, both locally and globally
Apr 1515:30
Conference pass
Models for drug discovery and development: how to generate relevant human data, increase both safety and efficiency, and reduce overall cost
Pre-Conference Seminar
Misti Ushio, Chief Executive Officer, Tara Biosystems
Apr 1516:00
Conference pass
Vendor management and compliance: how to collaborate on safety operations in SME pharma and biotechs
Pre-Conference Seminar
Different appraches for biotechs and SME pharma to compliance
Nneka Okere, Senior Manager, Global Drug Safety, Amicus Therapeutics Inc
Apr 1516:10
Conference pass
Panel
Insife Workshops
Implementing cloud strategies and creatively analyzing data
Create your personal agenda –check the favourite icon
Apr 1608:50
Conference pass
Opening remarks
Keynotes
Susan Welsh, Chief Safety Officer, CSL Behring
Apr 1609:00
Conference pass
Collaboration: utilizing cross-company teams for PV initiatives - how Transcelerate prepares for four massive projects
Keynotes
Jose Vega, Chief Safety Officer, Merck
Apr 1609:20
Conference pass
Proactive strategy: bringing a lean biotech approach to big pharma using early value assessment - improving safety and lowering cost
Keynotes
Alexandre Kiazand, Chief Safety Officer, AstraZeneca
Apr 1609:40
Conference pass
AI and Machine Learning: Using advanced technologies to help make PV operations more efficient
Keynotes
Bruce Palsulich, Vice President Product Strategy, Oracle Health Sciences
Apr 1611:00
Conference pass
Methods of signal collection and its influence on risk management: how your approach to signal detection affects data management and senior level decision making
PV METHODOLOGY
Daniel Seekins, Head, Medical Safety Assessment Innovative Medicines & Mature Products; Head, Global Safety Risk Man, Bristol Myers Squibb
Apr 1611:00
Conference pass
Growing companies and safety efficiencies: How to build safety programs of scale and implement them across company locations to maximize safety efficiency
GLOBAL PV
Stewart Geary, Senior Vice President, Chief Medical Officer, Director, Corporate Medical Affairs Headquarters, EISAI
Apr 1611:00
Conference pass
Understanding Toxicology: How understanding drug product attributes, toxicology study design, and measures of toxicity can help assess safety for moving into clinical trials
PREDICTIVE SAFETY
Jennifer Brown, Associate Director of Toxicology, MacroGenics, Inc.
Apr 1611:20
Conference pass
Mitigating patient risk through assessment of data: how to strategically combine human and artificial intelligence to improve your methodology in your approaches to risk
PV METHODOLOGY
Oscar Gonzalez, Director, Global Safety Officer, Sanofi Genzyme Corp
Apr 1611:20
Conference pass
Real world data and PV analytics in the rare disease landscape: How utilizing social media as a data collection source and incorporating innovative analytics can help your company assess rare disease
NEXT GEN TECH & DATA
Ale Maria Vazquez-Gragg, Vice President Of Global Patient Safety, Argenx
Apr 1611:20
Conference pass
Panel: Outsourcing vs. innovation
GLOBAL PV
How to lower costs, mitigate risk, and approach the differences in implementing safety procedures when globally outsourcing vs. implementing new technological innovation.
Richard Wolf, Senior Director, Global Clinical Operations And Pharmacovigilance, C.S.L. Behring Gmbh
Vicki Edwards, Qppv And Vp For Pharmacovigilance Excellence, AbbVie
Maria Tello, Head Of Safety, Rakuten Aspyrian
Apr 1611:20
Conference pass
The Nonclinical Innovation and Patient Safety Initiative (NIPSI): supporting human-based non-clinical approaches through global advances in regulation, policy, science, education and training
PREDICTIVE SAFETY
Elizabeth Baker, Pharmaceutical Policy Program Director, Physicians Committee for Responsible Medicine
Apr 1611:40
Conference pass
Risk management development: a case study in using desensitization for preventing adverse events in patients with allergies
PV METHODOLOGY
Adrian Dana, Vice President, Drug Safety, Aimmune Therapeutics
Apr 1611:40
Conference pass
Integration of continuum safety evidence for decision making
NEXT GEN TECH & DATA
How to assess the multi-source of real world safety data and consider design for RCT/PCT, observational trials, and post-marketing surveillance .
Lian Lin, Senior Statistician In Clinical Safety Statistics, Merck & Co
Ed Whalen, Director In Clinical Statistics, Pfizer
Apr 1611:40
Conference pass
How to utilize toxicity data in team decision making: how linking preclinical data to predictive safety can be applied to making executive decisions
PREDICTIVE SAFETY
Tom Parry, Toxicologist And Pharmacologist, Ovid Therapeutics
Apr 1612:00
Conference pass
Managing the Aura of Artificial Intelligence: how to advance the needs of patients through realistic strategies and align the human workforce with artificial intelligence
PV METHODOLOGY
April Davis, Global Pharmacovigilance Industry Director, Accenture
Apr 1612:00
Conference pass
Software for PV: how to incorporate software to store data, process cases, and centralize coding in your PV operations
NEXT GEN TECH & DATA
Aman Wasan, Vice President for Global Pharmacovigilance & Global Client Partners Group, ArisGlobal
Apr 1613:40
Conference pass
1) Small vs. large pharma: differences in approaches to methodology and risk
Keynotes
Bill Haddock, Head Of Safety, Ovid Therapeutics
Nicole Baker, Eea Qppv, Head Of Global Pharmacovigilance, Besins Healthcare
Apr 1613:40
Conference pass
10) 21st Century Reporting: How to properly, efficiently, and compliantly handle adverse event reports in today’s segmented digital age
Keynotes
Elena Davison, Director of Global Pharmacovigilance Informatics, Sunovion Pharmaceuticals
Apr 1613:40
Conference pass
11) Bridging your safety database to meet global R3 requirements: how to adjust your safety database to meet E2B(R3) requirements
Keynotes
Vladimir Laguerre, Founding Partner, Prudentia Group LLC
Sandeepa Raina, Director, Safety Information Management, Analytics & Process Excellence, Celgene
Apr 1613:40
Conference pass
2) Benefit Risk Discussion: comparing differences in approaches to benefit risk assessment and strategy
Keynotes
Quazi Ataher, Senior Director, Epidemiology. Worldwide Safety And Regulatory, Pfizer
Amgad Shebl, Director Of Global Clinical Safety And Pharmacovigilance, CSL Behring
Sophia Goodison, Director, Benefit Risk Evaluation, GSK
Apr 1613:40
Conference pass
3) Brexit and PV: How the United Kingdom’s retreat from the European Union continues to affect pharmacovigilance and patient safety
Keynotes
Vicki Edwards, Qppv And Vp For Pharmacovigilance Excellence, AbbVie
Apr 1613:40
Conference pass
4) Affiliate Pharmacovigilance Transformation
Keynotes
How to build a high-performing, sustainable and nimble Affiliate PV system that addresses the challenges of rising local volume of adverse event case processing, increasingly diverse local regulatory obligations and internal pressures to realize the value of safety in affiliate business strategies.
Gabrielle Sellick, Director, AbbVie
Kevin Tynan, Consultant, Global Clinical Safety and Pharmacovigilance, CSL Behring
Kemi Yusuf, Senior Director, Office Of The Product Safety Team And Pv Portfolio Management, AbbVie
Peter De Veene, QPPV, Alexion Pharmaceuticals
Apr 1613:40
Conference pass
5) Using automation to decrease errors: how computerized physician order entry, medication administration records, and discharge prescriptions and instructions can decrease errors and adverse events
Keynotes
Fatima Yousef Ali Ghethan, Head Of Quality and Medication Safety unit, King Abdullah Medical City
Apr 1613:40
Conference pass
6) Social media signal detection: How it has or has not worked and potential ways to implement it in your company
Keynotes
Ale Maria Vazquez-Gragg, Vice President Of Global Patient Safety, Argenx
Shaun Comfort, Safety Science Principal Medical Director At Genentech, Genentech A Member of the Roche Group Inc
Apr 1613:40
Conference pass
7) Emerging Markets - Implementing Infrastructure: the benefits of improving safety, incorporating Corporate Social Responsibility, and lowering long term cost
Keynotes
Maria Tello, Head Of Safety, Rakuten Aspyrian
Daniel Ciriano, Regional Medical Director, Roche SA
Raj Long, Deputy Director, Integrated Development, Global Health, The Bill & Melinda Gates Foundation
Andrea Maulwurf, Head Of Pharmacovigilance, Eu-Qppv, Allergy Therapeutics
Elias Kouchakji, Vice President Of Clinical Development And Drug Safety, Fibro Gen Inc
Apr 1613:40
Conference pass
8) RWA Linking Pre-Clinical and Post Marketing Toxicology Data: applications of predictive safety and how to utilize them in your company
Keynotes
Jane Gunther, Director Of Toxicology, Nektar Therapeutics
Mark Bluth, Senior Scientist, Bluth Bio Industries
Apr 1613:40
Conference pass
9) Regulatory requests for large post authorization studies from multiple companies
Keynotes
How to organize class-related post-authorization studies (Art. 31), obtain/analyze data across regions, communicate with different national authorities, and manage stakeholder expectations.
Michael Von Forstner, Chair, Pharmacovigilance Working Group, Medicines for Europe
Apr 1614:50
Conference pass
Aggregate safety assessment planning
PV METHODOLOGY
How leveraging multi-disciplinary management teams, conducting blinded safety monitoring procedures, and examining interviews with 20 thought leaders can help you mitigate risk and approach regulatory reviews.
Greg Ball, Senior Principal Statistician, Merck & Co
Barbara Hendrickson, Therapeutic Area Head, Abbvie S.A
Lothar Tremmel, Head, Biostatistics and Medical Writing, CSL Behring
Apr 1614:50
Conference pass
Statistical methods for signal management: how your approach to new regulatory requirements and confirming data with real world evidence can help you optimize the potential of your safety database
NEXT GEN TECH & DATA
Andres Gomez, Head Of Epidemiology, Safety Science And Analytics, Bristol Myers Squibb
Apr 1614:50
Conference pass
PV regulatory intelligence: how the regulatory environment in emerging markets affects the safety structure for your acquisitions in foreign countries and the local safety officers’ roles
GLOBAL PV
Andrea Maulwurf, Head Of Pharmacovigilance, Eu-Qppv, Allergy Therapeutics
Apr 1614:50
Conference pass
Translational safety management: how to approach the transition from non-clinical to clinical safety and its impact on predictive safety
PREDICTIVE SAFETY
Ignacio Rodriguez, Clinical Safety Therapeutic Area Head, Global Clinical Safety And Pharmacovigilance, CSL Behring
Apr 1615:10
Conference pass
AstraZeneca’s Benefit Risk Assessment Team (BRAT): how a cross functional team and a holistic approach to safety has helped AstraZeneca shift from reactive to proactive safety procedures
PV METHODOLOGY
Richard Hermann, Safety Science Physician, AstraZeneca
Apr 1615:10
Conference pass
The future of signal detection: harmonizing data standards, global databases, and open access/communication
NEXT GEN TECH & DATA
Mircea Ciuca, Global Head Of Medical And Clinical Drug Safety, Vifor Pharma
Apr 1615:10
Conference pass
The changing regulatory landscape in China, Japan, and Australia: how joining the ICH is affecting transparency, increasing the number of inspections, and changing data acquisition
GLOBAL PV
Lana Gloukhova, Head Of Regions, CSL Behring
Apr 1615:10
Conference pass
Predictive safety to prevent pain and suffering: how the clinical laboratory can utilize predictive safety to avoid adverse events in both trials and post market populations
PREDICTIVE SAFETY
Martin Bluth, Founder, Bluth Bio Industries
Apr 1615:30
Conference pass
Quantitative Benefit Risk Assessment: Pfizer’s approach to qBRA and its implications on PV
PV METHODOLOGY
Quazi Ataher, Senior Director, Epidemiology. Worldwide Safety And Regulatory, Pfizer
Apr 1615:30
Conference pass
Developing signal detection capabilities in real world data: how to leverage RWD more widely to increase effectiveness and approach models that lack a gold standard for comparison
NEXT GEN TECH & DATA
Qing (Kathy) Li, Director, Epidemiology, Worldwide Safety And Regulatory, Pfizer
Apr 1615:30
Conference pass
Implementation of PV following an acquisition: how to approach cultural barriers in safety management among local vendors and new training methods
GLOBAL PV
Mariette Boerstoel, Senior Vice President And Head Of Global Drug Safety, Alexion Pharmaceuticals
Apr 1615:30
Conference pass
Liver toxicity in clinical trials: how to apply liver safety data to avoid drug induced liver injury
PREDICTIVE SAFETY
Javier Waksman, Executive Director, Drug Safety, Fibro Gen Inc
Apr 1616:40
Conference pass
Think globally, report locally: how safety reporting technology and strategic utilization of local laws has enabled Roche to save $80M and overcome the complex processes of global harmonization
Keynotes
Steven Beales, Senior Vice President Of Information Technology, WCG Clinical
Apr 1617:00
Conference pass
The digital revolution and implications for pharmacovigilance: using technology platforms to transform data analytics, risk management and the implementation of PV programs
Keynotes
Sundeep Sethi, Vice President, Safety Operations, AbbVie
Create your personal agenda –check the favourite icon
Apr 1708:55
Conference pass
Chairperson opening remarks:
Keynotes
Susan Welsh, Chief Safety Officer, CSL Behring
Apr 1709:00
Conference pass
A new approach to developing advanced drug safety solutions
Keynotes
Using access to a wide range of information, including medical journals, regulatory filings, and relevant scientific data to help inform analytics and create more efficient PV operations.
Sherry Winter, Product Marketing Manager, Elsevier
Apr 1711:00
Conference pass
Methodologies with regards to filing for approval
PV METHODOLOGY
Overcoming relatively low regulatory approval rates for ATMPs through consistency in quality, a thorough dossier, and safety-inclusive clinical development models.
Barbara Morollo, Head, Pharmacovigilance Operations, Moderna Therapeutics
Apr 1711:00
Conference pass
A case study in automation: using strategy to improve accuracy, increase efficiency, and generate hypotheories
NEXT GEN TECH & DATA
Arvind Bellur, Director, Head Of Safety Data Management, Sanofi
Apr 1711:00
Conference pass
Patient Centricity: how to integrate new technology to monitor quality and compliance and improve patient outcomes
PATIENT SAFETY & MEDICAL DEVICES
Toyin Adewole, Drug Safety Associate Director, Supernus Pharmaceuticals, Inc.
Apr 1711:00
Conference pass
Predictive toxicity and using models to assess safety: case study examples on targeting safety, identifying an issue, and using different models to assess whether that issue is on/off target
PREDICTIVE SAFETY
Andrew Olaharski, Senior Toxicology Director, K.S.Q. Therapeutics
Apr 1711:20
Conference pass
Panel: CAR-T, RNA, and viral vectors: differences in post market monitoring for cell therapies, utilizing data, and scaling studies for ATMPs
PV METHODOLOGY
Moderator: William O'Brien, Chairman Of Medical Surveillance Team And Virology, Global Pharmacovigilance And Epidemiology, Bristol Myers Squibb
David Chonzi, Head Of Patient Safety And Pharmacovigilance, Kite, A Gilead Company
Ashlyn Bassiri, Pharmacovigilance Lead, Spark Therapeutics
Apr 1711:20
Conference pass
Apps as medical devices
PATIENT SAFETY & MEDICAL DEVICES
How apps have improved the patient experience, how companies are developing intuitive usage to improve safety, and how to approach the differences in regulations for medical devices.
Apr 1711:20
Conference pass
Use of human iPSC-derived cardiomyocytes and iPSC-derived neurons in-vitro models: the human imperative for better science and safer medicines
PREDICTIVE SAFETY
Frederick Sannajust, Executive Director, Head Of Safety And Exploratory Pharmacology,, Merck & Co
Apr 1711:40
Conference pass
The hidden challenges in machine learning and how to overcome them: validating post market findings, navigating regulations, and acting as first mover
NEXT GEN TECH & DATA
Apr 1711:40
Conference pass
Combination products and safety monitoring devices
PATIENT SAFETY & MEDICAL DEVICES
How to employ safety surveillance methods in clinical trials, assess signals in data systems, and decide when to use early termination to protect patient safety.
Apr 1711:40
Conference pass
Enhanced evaluation of drug induced hepatotoxicity
PREDICTIVE SAFETY
How to use the interactive safety graphic tool to analyze drug induced liver injury data values across varying platforms to increase efficiency and reliability of your PV models.
Jim Buchanan, Clinician, Covilance, LLC
Xiao Ni, Lead Statistician For Ophthalmology In Early Development Biostatistics, Novartis
Apr 1712:00
Conference pass
The Future of PV Automation: how to examine PV across time to increase efficiencies by reducing the level of human intervention
NEXT GEN TECH & DATA
Dinesh Kasthuril, Client Director, Sciformix Corp
Apr 1713:40
Conference pass
1) PV processes in Africa and Asia: how to implement new processes and adapt to change in these regions
Keynotes
Nicole Baker, Eea Qppv, Head Of Global Pharmacovigilance, Besins Healthcare
Apr 1713:40
Conference pass
10) Deep Dive into the Technology & Processes Behind the Roche Clinical Trial Safety Portal
Keynotes
A case study in eliminating over-distribution and improving patient safety, while significantly reducing costs.
Steven Beales, Senior Vice President Of Information Technology, WCG Clinical
Apr 1713:40
Conference pass
11) Using AI to predict toxicity: how early stage AI can help identify downstream toxicity risks and explain their underlying causes
Keynotes
Neel Madhukar, CEO, OneThree Biotech
Coryandar Gilvary, Vice President of Computational Biology, OneThree Biotech
Apr 1713:40
Conference pass
12) The role of patient preference studies in supporting benefit-risk profiles: how to determine the impact on a specific product/disease area, identify key therapeutic decisions, and obtain alignment
Keynotes
Leo Russo, Senior Director, Epidemiology Worldwide Safety & Regulatory, Pfizer
Apr 1713:40
Conference pass
2) Signal Detection: data sources, challenges, and innovative approaches
Keynotes
Rudi Scheerlinck, Global Head Pharmacovigilance Risk Management, Nestle Skin Health
Apr 1713:40
Conference pass
3) Reference safety information: RSI used in Clinical Trials based on the CTFG RSI Q&A Document and the EFPIA Draft Paper in response to such document
Keynotes
Maritess Esguerra, Principal Pharmacovigilance Process Leader, Genentech
Mariette Boerstoel, Senior Vice President And Head Of Global Drug Safety, Alexion Pharmaceuticals
Apr 1713:40
Conference pass
4) Cell Therapies: Understanding the safety requirements and post marketing monitoring processes
Keynotes
David Chonzi, Head Of Patient Safety And Pharmacovigilance, Kite, A Gilead Company
Apr 1713:40
Conference pass
5) Combination Product Regulations: differences in regulatory approaches for combination products and how to streamline your company’s strategy
Keynotes
Lykke Bjerglund Graff, Head of Global Safety, LEO Pharma
Kirsten Paulson, Senior Director Global Cmc-Medical Devices, Pfizer
Apr 1713:40
Conference pass
6) Using AI to optimize workloads: How AI can facilitate organizational design, create a continued learning mindset, and standardize data to ease the workload on your team
Keynotes
Lena Mishalov, Director, PV Technological Innovations, Astellas
Saberi Rana Ali, Medical Safety Officer, Established Products Global Medical Safety, Janssen Pharmaceutical companies of Johnson & Johnson
Omar Aimer, Pharmacovigilance Specialist, Sanofi
Detlef Hold, Global Strategy Lead, Knowledge Cycling, Genentech
Apr 1713:40
Conference pass
7) PV regulatory changes in Russia and Eurasia: how to approach regulations in these areas and create a strategy for your company
Keynotes
Vladimir Andrianov, Head Of Scientific Studies Department, Institute of Interdisciplinary Medicine
Kevin Tynan, Consultant, Global Clinical Safety and Pharmacovigilance, CSL Behring
Apr 1713:40
Conference pass
8)Preventative safety and cross functional teams: How to communicate across teams and implement interdepartmental strategy
Keynotes
Tanja Fahlbusch, Senior Expert International Pharmacovigilance, Process Liaison, Roche
Apr 1713:40
Conference pass
9) Small bio startups: how to approach regulatory changes, implement PV programs, and provide training and support without wasting limited resources
Keynotes
Hedva Voliovitch, Vice President Of Director Of Pharmacovigilance, Teva Pharmaceutical lndustries Ltd
Apr 1714:50
Conference pass
Harmonizing literature monitoring: how to approach the diversity in application and interpretation of literature monitoring guidelines
PV METHODOLOGY
Suzanne Berresford, Product Director Adis Pharmacovigilance, Springer Nature
Apr 1714:50
Conference pass
Reimagining PV with the adoption and implementation of AI & machine learning: approaching signal management, causality assessment, aggregate analysis, and literature management
NEXT GEN TECH & DATA
Krishna Asvalayan, Senior Director, Head of Functional Services, Ancla
Apr 1714:50
Conference pass
Safety Evaluation in Early Phase Oncology : how to identify opportunities in Early Clinical Development for safety profile characterization and expedite development through FDA guidance on early oncol
PREDICTIVE SAFETY
William Wang, Executive Director, Clinical Safety Statistics, Merck
Oswaldo Bracco, Associate Vice President, Clinical Safety And Risk Management, Merck & Co
Apr 1715:10
Conference pass
Panel: Methodologies for implementation of PV programs: how to approach local regulations, use software to your advantage, and optimize leads to improve success rates
PV METHODOLOGY
Daniel Ciriano, Regional Medical Director, Roche SA
William Wang, Executive Director, Clinical Safety Statistics, Merck
Deepa Venkataraman, Senior Director, Section Head, Drug Safety And Pharmacovigilance Operations, Pharmacyclics
Apr 1715:10
Conference pass
PV Automation & Implementation: how adopting and properly implementing automation in your PV operations can save money and create efficiency
NEXT GEN TECH & DATA
Francois Audibert, Vice President Of Us Operations, Vitrana
Apr 1715:10
Conference pass
Patient studies: how to define synthetic cohorts to ensure accuracy in clinical trials
PATIENT SAFETY & MEDICAL DEVICES
Jie Li, Senior Director Global Patient Safety, Sanofi Aventis
Apr 1715:10
Conference pass
Dose-limiting toxicity: how to understand DLT in oncology clinical trials and approach challenges with modern agents and combination therapies
PREDICTIVE SAFETY
Yolanda Yang, Senior Director, Medical Safety Science, Acerta Pharma
Apr 1715:30
Conference pass
Unstructured data analytics: how to utilize language processing technology, text mining, and increased data accessibility to scan literature databases and improve your analytics
NEXT GEN TECH & DATA
Veronica Urdaneta, Senior Principal Scientist/ Physician, Merck
Apr 1715:30
Conference pass
Patient reported adverse events: how to communicate safety or tolerability data, identify non-clinical data needed, and compile evidence for tolerability to build a patient profile
GLOBAL PV
Nneka Onwudiwe, Founder and Chief Executive Officer, Pharmacoeconomics Consultants of America
Apr 1715:30
Conference pass
Safety Evaluation in Early Phase Oncology
PREDICTIVE SAFETY
How to identify opportunities in Early Clinical Development for safety profile characterization and expedite development through FDA guidance on early oncology trials.
William Wang, Executive Director, Clinical Safety Statistics, Merck
Oswaldo Bracco, Associate Vice President, Clinical Safety And Risk Management, Merck & Co
Apr 1715:55
Conference pass
Chairperson Closing Remarks:
Keynotes
Susan Welsh, Chief Safety Officer, CSL Behring
last published: 06/Mar/19 17:05 GMT
Get Involved At World Drug Safety Congress Americas
Organiser
